Clinical trials: Traveler's Diarrhea
Acute Gastroenteritis in Adult Travelers
Safety and Efficacy of Prulifloxacin Versus Placebo in Traveler's Diarrhea
The objective of this pivotal Phase III study is to investigate the safety and efficacy of prulifloxacin versus placebo in the treatment of subjects with acute bacterial gastroenteritis.
- Trial name
- NCT00392574
- Testing
- Prulifloxacin
- Where
- United States
- Volunteers
- 282 people
- Sponsor
- Merck Sharp & Dohme LLC
Diarrhea
Prevention of Travelers' Diarrhea in Subjects Traveling Outside the U.S.
The primary objective of this study is to assess the safety and tolerability of rifaximin 600 mg (3 x 200-mg tablets) once daily compared with placebo when taken for 14 days by healthy subjects to prevent travelers' diarrhea (TD)…
- Trial name
- NCT00328380
- Testing
- Rifaximin
- Where
- 3 sites in United States
- Volunteers
- 660 people, healthy volunteers welcome
- Sponsor
- Bausch Health Americas, Inc.
Prevention of Travelers' Diarrhea
LT Vaccine Patch Self-Administration Study
To evaluate the immune responses achieved following self-administered heat-labile enterotoxin of E. coli (LT) vaccination by transcutaneous immunization compared to the immune responses achieved by clinician-administered…
- Trial name
- NCT00565461
- Testing
- heat-labile enterotoxin of E. coli (LT)
- Where
- 3 sites in United States
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Intercell USA, Inc.
Travelers' Diarrhea
A Study Comparing Two Rifaximin Tablets in Patients With Travelers' Diarrhea.
This study compared safety and efficacy of a generic rifaximin tablet to the reference listed drug in the treatment of travelers' diarrhea.
- Trial name
- NCT02920242
- Testing
- Rifaximin (Sandoz GmbH) tablet, Rifaximin (Xifaxan)
- Where
- Mexico
- Volunteers
- 28 people
- Sponsor
- Sandoz
Diarrhea
Study Comparing Rifaximin With Xifaxan 200 mg in Traveler's Diarrhea
The primary objective is to demonstrate rifaximin 200 milligrams (mg) tablets (test) and Xifaxan® 200 mg tablets (reference) are clinically bioequivalent with respect to the clinical cure rates when administered 3 times a day…
- Trial name
- NCT02498418
- Testing
- Rifaximin, Xifaxan®
- Where
- United States
- Volunteers
- 739 people
- Sponsor
- Actavis Inc.
Traveler's Diarrhea
Rifamycin SV-MMX® Tablets Versus Ciprofloxacin Capsules in Acute Traveller's Diarrhoea
The purpose of this study is to prove the non-inferiority of Rifamycin SV-MMX® versus Ciprofloxacin for the treatment of adults with traveller's diarrhoea.
- Trial name
- ERASE (NCT01208922)
- Testing
- Rifamycin SV-MMX®, Ciprofloxacin
- Where
- 19 sites in Ecuador, Guatemala and 1 more
- Volunteers
- 835 people
- Sponsor
- Dr. Falk Pharma GmbH
Diarrhea, Travelers Diarrhea
Clinical Study to Assess the Efficacy of Once-daily IMM-124E (Travelan®) in a Controlled Human Infection Model.
This is a randomized, double-blind, placebo-controlled study to investigate a single daily dose of Travelan® protects healthy adult volunteers from moderate-to-severe diarrhea upon challenge with Enterotoxigenic Escherichia coli…
- Conditions
- Diarrhea, Travelers Diarrhea, Infectious Diarrhea
- Trial name
- NCT05933525
- Testing
- Travelan
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Immuron Ltd.
Diarrhea
Safety and Immunogenicity Study of Traveler's Diarrhea Vaccine Patch
The purpose of this study is to evaluate and compare the safety and immune responses following a two vaccination regimen by transcutaneous immunization with heat-labile enterotoxin of E.
- Trial name
- NCT01067781
- Testing
- Heat-Labile Enterotoxin of E. coli (LT)
- Where
- 5 sites in United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Intercell USA, Inc.
Travelers Diarrhea
Etiology of Travelers' Diarrhea in Australian Tourists Traveling to Southeast Asia
The study proposed here will determine the frequency and etiology of diarrhea in Australian adult tourists traveling to Southeast Asia, including Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines, Thailand…
- Trial name
- AusTD (NCT06363890)
- Testing
- TAQMan Array Card
- Where
- Australia
- Volunteers
- 2,400 people, healthy volunteers welcome
- Sponsor
- Lumen Bioscience, Inc.
Travelers' Diarrhea
Probiotics and the Prevention of Traveler's Diarrhea
The present study is designed to evaluate the effect of a mixture of probiotics on the prevention of traveler's diarrhea (TD) in subjects who travel to a country with a high risk for developing TD.
- Trial name
- TD (NCT01005849)
- Testing
- Protecflor
- Where
- Italy
- Volunteers
- 420 people, healthy volunteers welcome
- Sponsor
- Lallemand SAS
Acute Bacterial Gastroenteritis
Safety and Efficacy of Prulifloxacin vs Placebo in Treatment of Acute Gastroenteritis in Adult Travelers
The objective of this pivotal Phase III study is to investigate the safety and efficacy of prulifloxacin versus placebo in the treatment of patients with acute bacterial gastroenteritis (traveler's diarrhea.
- Trial name
- NCT00448422
- Testing
- prulifloxacin
- Where
- India
- Volunteers
- 268 people
- Sponsor
- Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Prevention of Travelers' Diarrhea
Traveler's Diarrhea (TD) Automated Process
To evaluate and compare the immune responses and safety following a two vaccination regimen by transcutaneous immunization with heat-labile enterotoxin of E. coli (LT) patches or placebo patches.
- Trial name
- NCT00751777
- Testing
- heat-labile enterotoxin of E. coli (LT)
- Where
- 3 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Intercell USA, Inc.
Traveler's Diarrhea
Study to Evaluate Safety and Efficacy of Rifamycin SV MMX in Treating Traveler's Diarrhea in Children Age 12 to 17 Years
This will be a double blind comparative study, performed in pediatric subjects (Age 12-17) traveling to developing regions with a known high incidence of traveler's diarrhea.
- Trial name
- NCT04027894
- Testing
- Rifamycin SV MMX
- Volunteers
- 142 people
- Sponsor
- RedHill Biopharma Limited
Diarrhea
Safety and Efficacy Study of a Vaccine Against Enterotoxigenic Escherichia Coli (ETEC) to Prevent Moderate to Severe Diarrhea
This is a research study about an experimental (investigational) vaccine called ACE527. ACE527 is a vaccine that is being made to prevent disease from a germ called enterotoxigenic Escherichia coli (ETEC).
- Trial name
- NCT01060748
- Testing
- ACE527
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- TD Vaccines A/S
Campylobacter Infection
ACE393-103 Vaccination Challenge Study
The purpose of this study is to determine whether ACE393 vaccination can protect against Campylobacteriosis in a challenge model.
- Trial name
- ACE393-103VC (NCT00859716)
- Testing
- ACE393
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- TD Vaccines A/S
Enterotoxigenic E. Coli (ETEC) Infection
ACE527 Safety and Immunogenicity Study
The purpose of this study is to evaluate the safety and immune response to ACE527.
- Trial name
- NCT00901654
- Testing
- ACE527 vaccine
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- TD Vaccines A/S
Traveler's Diarrhea
Traveler's Diarrhea (TD) Vaccine Asia Efficacy Study
The purpose of this study is to evaluate the efficacy of the TD Vaccine System to prevent moderate to severe enterotoxin E.coli (ETEC) disease in travelers to India.
- Trial name
- NCT01040325
- Testing
- TD Vaccine System
- Where
- 12 sites in Germany, India and 1 more
- Volunteers
- 723 people, healthy volunteers welcome
- Sponsor
- Intercell USA, Inc.
Traveler's Diarrhea
Clinical Trial of CBS-2004 in Prevention of Travelers' Diarrhea
This study is designed as a randomized double-blinded treatment trial among travelers' to geographical areas with moderate-severe rates of traveler's diarrhea.
- Trial name
- NCT02736539
- Testing
- CBS 2004 (galacto-oligosaccharides)
- Volunteers
- healthy volunteers welcome
- Sponsor
- Clasado Biosciences Ltd
Diarrhea
Rifaximin for Prevention of Travellers' Diarrhea
The purpose of this study is to determine if 600 mg of rifaximin, taken once a day for 14 days by healthy subjects, is safe and effective for the prevention of travellers' diarrhea compared to placebo.
- Trial name
- NCT00742469
- Testing
- Rifaximin
- Where
- Mexico
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Bausch Health Americas, Inc.
Traveler's Diarrhea
Prevention, Randomized, Double-Blinded, Placebo-Controlled, Parallel Assignment, Safety/Efficacy Study
The main purpose of this study is to evaluate the body's immune response to the LT patch at different doses. The secondary purpose of this study is to evaluate the safety of the LT patches at different doses and the safety of the…
- Trial name
- NCT00672035
- Testing
- Biological: heat-labile enterotoxin of E. coli (LT)
- Where
- 5 sites in United States
- Volunteers
- 406 people, healthy volunteers welcome
- Sponsor
- Intercell USA, Inc.